Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report

RET-rearranged fusions have been considered as oncogenic drivers in 1% to 2% of non-small cell lung cancers (NSCLC). ARROW study has demonstrated a new selective RET tyrosine kinase inhibitors (TKIs) shows remarkable and durable responses in RET-rearranged NCSLC. In this study mainly recruited patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Linping, Ji, Wenxiang, Xu, Yunhua, Han, Yuchen, Jian, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704906/
https://www.ncbi.nlm.nih.gov/pubmed/36451418
http://dx.doi.org/10.1097/MD.0000000000031480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704906/
https://www.ncbi.nlm.nih.gov/pubmed/36451418
http://dx.doi.org/10.1097/MD.0000000000031480

Ejemplares similares